Option Care Health (OPCH)
NASDAQ:OPCH
OPCH Stock Chart & Stats
$28.93
-$0.14(-0.58%)
At close: 4:00 PM EST
$28.93
-$0.14(-0.58%)
Day’s Range― - ―
52-Week Range$24.24 - $36.80
Previous CloseN/A
Volume256.90K
Average Volume (3M)1.72M
Market Cap
$4.54B
Enterprise Value$4.29B
Total Cash (Recent Filing)$232.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)24.3
Beta0.40
Next Earnings
Apr 30, 2026EPS Estimate
0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.46
Shares Outstanding156,447,970
10 Day Avg. Volume1,639,360
30 Day Avg. Volume1,717,859
Financial Highlights & Ratios
PEG Ratio5.98
Price to Book (P/B)3.80
Price to Sales (P/S)0.89
P/FCF Ratio19.51
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue0.76
Enterprise Value/Gross Profit3.95
Enterprise Value/Ebitda9.24
Forecast
1Y Price Target
$40.33Price Target Upside39.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.87
Revenue Forecast (FY)$5.94B
Bulls Say, Bears Say
Bulls Say
Guidance And Cash FlowCompany affirmed financial guidance and expects a meaningful increase in cash flow from operations, supporting operational stability and funding for growth initiatives.
Product Portfolio And PipelineReliance on a single therapy has been materially reduced and ongoing pipeline activity with new drug introductions positions the company to resume stronger revenue growth and expand margins.
Share Repurchases And Capital AllocationBoard approved a meaningful increase in the share repurchase authorization, signaling stronger focus on returning capital to shareholders and confidence in future cash generation.
Bears Say
Inventory Unwind And SeasonalityUnwinding of a prior inventory-driven sales boost and seasonal patient behavior create tougher comparisons that may soften reported revenue growth and limit upside surprises.
Pricing Pressure From Biosimilars And PolicyPricing changes and increased biosimilar competition are likely to reduce gross profits for affected therapies and compress overall margins.
Therapy-specific Revenue PressureStelara-related headwinds are expected to create a revenue and gross profit drag that could pressure near-term results and cause uneven quarterly performance.
Option Care Health News
OPCH FAQ
What was Option Care Health’s price range in the past 12 months?
Option Care Health lowest stock price was $24.23 and its highest was $36.80 in the past 12 months.
What is Option Care Health’s market cap?
Option Care Health’s market cap is $4.54B.
When is Option Care Health’s upcoming earnings report date?
Option Care Health’s upcoming earnings report date is Apr 30, 2026 which is in 16 days.
How were Option Care Health’s earnings last quarter?
Option Care Health released its earnings results on Feb 24, 2026. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.469 by -$0.009.
Is Option Care Health overvalued?
According to Wall Street analysts Option Care Health’s price is currently Undervalued.
Does Option Care Health pay dividends?
Option Care Health does not currently pay dividends.
What is Option Care Health’s EPS estimate?
Option Care Health’s EPS estimate is 0.38.
How many shares outstanding does Option Care Health have?
Option Care Health has 156,447,970 shares outstanding.
What happened to Option Care Health’s price movement after its last earnings report?
Option Care Health reported an EPS of $0.46 in its last earnings report, missing expectations of $0.469. Following the earnings report the stock price went down -6.304%.
Which hedge fund is a major shareholder of Option Care Health?
Currently, no hedge funds are holding shares in OPCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Option Care Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.33 (39.41% Upside)
$40.33 (39.41% Upside)
Blogger Sentiment
Bullish
OPCH Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 845.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.92%
12-Months-Change
Fundamentals
Return on Equity
15.39%
Trailing 12-Months
Asset Growth
0.81%
Trailing 12-Months
Company Description
Option Care Health
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
OPCH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a constructive operational and financial story: strong top-line growth, margin and automation gains, successful clinic and M&A integration, expanded pharma and payer partnerships, and a reaffirmation of 2026 guidance. Key near-term challenges include Stelara biosimilar-driven revenue and gross profit headwinds, a 2025 cash flow shortfall due to strategic inventory buys and elevated working capital needs, and persistent payer/market pressure. Management outlined concrete efficiency and cash-conversion actions and expects cash flow and EBITDA expansion in 2026, indicating confidence that headwinds are manageable.View all OPCH earnings summariesOPCH Stock 12 Month Forecast
Average Price Target
$40.33
▲(39.41% Upside)
Technical Analysis
Addus Homecare
―
Chemed
―
National Healthcare
―
Surgery Partners
―
Aveanna Healthcare Holdings
―
Ownership Overview
1.18% Insiders
39.11% Mutual Funds
29.23% Other Institutional Investors
4.09% Public Companies and
Individual Investors